
Celltrion Expands Product Portfolio in Oceania with Approvals for Eydenzelt and Stoboclo/Osenvelt in Australia
Celltrion announced on April 10 that it has received product approvals from the Australian Therapeutic Goods Administration (TGA) for the eye disease treatment Eydenzelt (active ingredient: Aflibercept) and the bone disease treatment Stoboclo-Osenvelt ( …